{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:26:44Z","timestamp":1792762004301,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02170-4","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T13:28:47Z","timestamp":1741786127000},"page":"475-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Update on the Treatment of Chronic Spontaneous Urticaria"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-8132","authenticated-orcid":false,"given":"Pavel","family":"Kolkhir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3450-0877","authenticated-orcid":false,"given":"Jie Shen","family":"Fok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-0959","authenticated-orcid":false,"given":"Emek","family":"Kocat\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-9162","authenticated-orcid":false,"given":"Philip H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-240X","authenticated-orcid":false,"given":"Tiia-Linda","family":"Okas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-8847","authenticated-orcid":false,"given":"Joao","family":"Marcelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-9976","authenticated-orcid":false,"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"1","key":"2170_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Gim\u00e9nez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. https:\/\/doi.org\/10.1038\/s41572-022-00389-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2170_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"issue":"17","key":"2170_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bonnekoh H, Metz M, et al. Chronic spontaneous urticaria: a review. JAMA. 2024;332(17):1464\u201377. https:\/\/doi.org\/10.1001\/jama.2024.15568.","journal-title":"JAMA"},{"issue":"2","key":"2170_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","volume":"75","author":"J Fricke","year":"2020","unstructured":"Fricke J, \u00c1vila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423\u201332. https:\/\/doi.org\/10.1111\/all.14037.","journal-title":"Allergy"},{"issue":"1","key":"2170_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","volume":"12","author":"M-M Balp","year":"2022","unstructured":"Balp M-M, Halliday AC, Severin T, et al. Clinical remission of chronic spontaneous urticaria (csu): a targeted literature review. Dermatol Ther (Heidelb). 2022;12(1):15\u201327. https:\/\/doi.org\/10.1007\/s13555-021-00641-6.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"2170_CR6","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, B\u00e9rard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005\u201316. https:\/\/doi.org\/10.1111\/all.13209.","journal-title":"Allergy"},{"issue":"2","key":"2170_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bjd.19561","volume":"184","author":"M Goncalo","year":"2021","unstructured":"Goncalo M, Gimenez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226\u201336. https:\/\/doi.org\/10.1111\/bjd.19561.","journal-title":"Br J Dermatol"},{"key":"2170_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.036","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bieber K, Hawro T, et al. Mortality in adult patients with chronic spontaneous urticaria: a real-world cohort study. J Allergy Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/j.jaci.2024.11.036.","journal-title":"J Allergy Clin Immunol"},{"key":"2170_CR9","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/jdv.20071","volume":"38","author":"M Augustin","year":"2024","unstructured":"Augustin M, Beier D, Branner J, et al. The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20071.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2170_CR10","doi-asserted-by":"publisher","first-page":"adv36122","DOI":"10.2340\/actadv.v104.36122","volume":"104","author":"A Baudy","year":"2024","unstructured":"Baudy A, Raison-Peyron N, Serrand C, et al. Impact of chronic spontaneous or inducible urticaria on occupational activity. Acta Derm Venereol. 2024;104:adv36122. https:\/\/doi.org\/10.2340\/actadv.v104.36122.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2170_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jaip.2022.11.016","volume":"11","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir P, Laires PA, Salameh P, et al. The benefit of complete response to treatment in patients with chronic spontaneous urticaria\u2014CURE results. J Allergy Clin Immunol Pract. 2023;11(2):610\u20136205. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.016.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2170_CR12","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.3390\/jcm12103561","volume":"12","author":"JA Bernstein","year":"2023","unstructured":"Bernstein JA, Gim\u00e9nez-Arnau A, Maurer M, et al. Why a complete response is the treatment aim in chronic spontaneous urticaria. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12103561.","journal-title":"J Clin Med"},{"issue":"1","key":"2170_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","volume":"155","author":"MD Tharp","year":"2019","unstructured":"Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u201creal-world\u201d evidence. JAMA Dermatol. 2019;155(1):29\u201338. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3447.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2170_CR14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","volume":"6","author":"K Kulthanan","year":"2018","unstructured":"Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586\u201399. https:\/\/doi.org\/10.1016\/j.jaip.2017.07.017.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2170_CR15","doi-asserted-by":"publisher","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. 2024;403(10422):147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","DOI":"10.1016\/S0140-6736(23)01684-7"},{"key":"2170_CR16","doi-asserted-by":"publisher","unstructured":"Altrichter S, Gim\u00e9nez-Arnau AM, Bernstein JA, et al. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial. Br J Dermatol 2024;ljae067. https:\/\/doi.org\/10.1093\/bjd\/ljae067.","DOI":"10.1093\/bjd\/ljae067"},{"key":"2170_CR17","doi-asserted-by":"publisher","unstructured":"Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743\u201367. https:\/\/doi.org\/10.1038\/s41573-023-00750-1.","DOI":"10.1038\/s41573-023-00750-1"},{"issue":"12","key":"2170_CR18","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/all.13949","volume":"74","author":"N Schoepke","year":"2019","unstructured":"Schoepke N, Asero R, Ellrich A, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study. Allergy. 2019;74(12):2427\u201336. https:\/\/doi.org\/10.1111\/all.13949.","journal-title":"Allergy"},{"issue":"6","key":"2170_CR19","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","volume":"149","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Mu\u00f1oz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819\u201331.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2170_CR20","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.jaip.2024.05.043","volume":"12","author":"G Mosnaim","year":"2024","unstructured":"Mosnaim G, Casale TB, Holden M, et al. Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab. J Allergy Clin Immunol Pract. 2024;12(9):2537\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2024.05.043.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"2170_CR21","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","volume":"11","author":"Y-K Xiang","year":"2023","unstructured":"Xiang Y-K, Kolkhir P, Scheffel J, et al. Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. J Allergy Clin Immunol Pract. 2023. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.006.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2170_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","volume":"128","author":"M Maurer","year":"2011","unstructured":"Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202\u20132095. https:\/\/doi.org\/10.1016\/j.jaci.2011.04.038.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2170_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12948-022-00171-2","volume":"20","author":"E Nettis","year":"2022","unstructured":"Nettis E, Brussino L, Patella V, et al. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy. 2022;20(1):6. https:\/\/doi.org\/10.1186\/s12948-022-00171-2.","journal-title":"Clin Mol Allergy"},{"issue":"3","key":"2170_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0091-6749(98)70140-x","volume":"102","author":"H Toru","year":"1998","unstructured":"Toru H, Pawankar R, Ra C, et al. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol. 1998;102(3):491\u2013502. https:\/\/doi.org\/10.1016\/s0091-6749(98)70140-x.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2170_CR25","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1398-9995.2012.02859.x","volume":"67","author":"M Komai-Koma","year":"2012","unstructured":"Komai-Koma M, Brombacher F, Pushparaj PN, et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in na\u00efve mice. Allergy. 2012;67(9):1118\u201326. https:\/\/doi.org\/10.1111\/j.1398-9995.2012.02859.x.","journal-title":"Allergy"},{"issue":"1","key":"2170_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/imr.12632","volume":"282","author":"MK Church","year":"2018","unstructured":"Church MK, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232\u201347. https:\/\/doi.org\/10.1111\/imr.12632.","journal-title":"Immunol Rev"},{"key":"2170_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879754","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou B, Li J, Liu R, et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol. 2022;13: 879754. https:\/\/doi.org\/10.3389\/fimmu.2022.879754.","journal-title":"Front Immunol"},{"key":"2170_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","volume":"17","author":"K Nelms","year":"1999","unstructured":"Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701\u201338. https:\/\/doi.org\/10.1146\/annurev.immunol.17.1.701.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2170_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2004-07-2838","volume":"105","author":"M Kulka","year":"2005","unstructured":"Kulka M, Metcalfe DD. High-resolution Tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: correlation with apoptosis and KIT expression. Blood. 2005;105(2):592\u20139. https:\/\/doi.org\/10.1182\/blood-2004-07-2838.","journal-title":"Blood"},{"issue":"3","key":"2170_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1084\/jem.173.3.747","volume":"173","author":"H Gascan","year":"1991","unstructured":"Gascan H, Gauchat JF, Roncarolo MG, et al. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med. 1991;173(3):747\u201350. https:\/\/doi.org\/10.1084\/jem.173.3.747.","journal-title":"J Exp Med"},{"issue":"14","key":"2170_CR31","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.1073\/pnas.96.14.8080","volume":"96","author":"SC Bischoff","year":"1999","unstructured":"Bischoff SC, Sellge G, Lorentz A, et al. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci USA. 1999;96(14):8080\u20135. https:\/\/doi.org\/10.1073\/pnas.96.14.8080.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2170_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000066772","volume":"129","author":"M Ferrer","year":"2002","unstructured":"Ferrer M, Luquin E, Sanchez-Ibarrola A, et al. Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol. 2002;129(3):254\u201360. https:\/\/doi.org\/10.1159\/000066772.","journal-title":"Int Arch Allergy Immunol"},{"key":"2170_CR33","unstructured":"Gao C, Chen WC, Liu W, et al. Pathogenic role of circulating CD4+CXCR5+ cell subpopulations in patients with chronic spontaneous urticarial. Am J Transl Res. 2020;12(8):4434\u201344."},{"issue":"5","key":"2170_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1034\/j.1600-0625.2003.00010.x","volume":"12","author":"M Caproni","year":"2003","unstructured":"Caproni M, Volpi W, Macchia D, et al. Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp Dermatol. 2003;12(5):621\u20138. https:\/\/doi.org\/10.1034\/j.1600-0625.2003.00010.x.","journal-title":"Exp Dermatol"},{"issue":"4","key":"2170_CR35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1067\/mai.2002.123236","volume":"109","author":"S Ying","year":"2002","unstructured":"Ying S, Kikuchi Y, Meng Q, et al. TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694\u2013700. https:\/\/doi.org\/10.1067\/mai.2002.123236.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2170_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2004.07.006","volume":"36","author":"M Caproni","year":"2004","unstructured":"Caproni M, Cardinali C, Giomi B, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci. 2004;36(1):57\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2004.07.006.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"2170_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/jdv.14541","volume":"32","author":"Q Chen","year":"2018","unstructured":"Chen Q, Zhong H, Chen WC, et al. Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2018. https:\/\/doi.org\/10.1111\/jdv.14541.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2170_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.926753","volume":"9","author":"C Prosty","year":"2022","unstructured":"Prosty C, Gabrielli S, Ben-Shoshan M, et al. In silico identification of immune cell-types and pathways involved in chronic spontaneous urticaria. Front Med. 2022;9: 926753. https:\/\/doi.org\/10.3389\/fmed.2022.926753.","journal-title":"Front Med"},{"key":"2170_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.028","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"key":"2170_CR40","unstructured":"Regeneron. Dupixent\u00ae (Dupilumab) phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria (CSU). https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/dupixentr-dupilumab-phase-3-trial-confirms-significant. 2024."},{"issue":"9","key":"2170_CR41","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","volume":"14","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels. Dermatol Ther (Heidelb). 2024. https:\/\/doi.org\/10.1007\/s13555-024-01231-y.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"2170_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/biom13040634","volume":"13","author":"H Olbrich","year":"2023","unstructured":"Olbrich H, Sadik CD, Ludwig RJ, et al. Dupilumab in inflammatory skin diseases: a systematic review. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13040634.","journal-title":"Biomolecules"},{"key":"2170_CR43","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1111\/all.15261","volume":"77","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton\u2019s tyrosine kinase inhibition\u2014an emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77:2355\u201366. https:\/\/doi.org\/10.1111\/all.15261.","journal-title":"Allergy"},{"issue":"8","key":"2170_CR44","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.187.8.1235","volume":"187","author":"D Hata","year":"1998","unstructured":"Hata D, Kawakami Y, Inagaki N, et al. Involvement of Bruton\u2019s tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med. 1998;187(8):1235\u201347. https:\/\/doi.org\/10.1084\/jem.187.8.1235.","journal-title":"J Exp Med"},{"issue":"5","key":"2170_CR45","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","volume":"153","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Maurer M, Saini SS. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2170_CR46","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.anai.2024.04.023","volume":"133","author":"I Puxeddu","year":"2024","unstructured":"Puxeddu I, Pistone F, Pisani F, et al. Mast cell signaling and its role in urticaria. Ann Allergy Asthma Immunol. 2024. https:\/\/doi.org\/10.1016\/j.anai.2024.04.023.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"2170_CR47","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1172\/jci138448","volume":"130","author":"MC Dispenza","year":"2020","unstructured":"Dispenza MC, Krier-Burris RA, Chhiba KD, et al. Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J Clin Invest. 2020;130(9):4759\u201370. https:\/\/doi.org\/10.1172\/jci138448.","journal-title":"J Clin Invest"},{"issue":"11","key":"2170_CR48","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","volume":"27","author":"M Metz","year":"2021","unstructured":"Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H 1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27(11):1961\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01537-w.","journal-title":"Nat Med"},{"key":"2170_CR49","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, et al. Long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies. In: Presented as a late oral abstract session on clinical trials at EAACI 2024; May 31\u2013June 3, 2024; Valencia, Spain."},{"issue":"5, Supplement","key":"2170_CR50","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.anai.2022.08.537","volume":"129","author":"W Carr","year":"2022","unstructured":"Carr W, Sitz K, Jain V, et al. Remibrutinib improves chronic spontaneous urticaria in patients irrespective of cu-index: results from phase 2b study. Ann Allergy Asthma Immunol. 2022;129(5, Supplement):S11. https:\/\/doi.org\/10.1016\/j.anai.2022.08.537.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2170_CR51","doi-asserted-by":"publisher","first-page":"AB369","DOI":"10.1016\/j.jaci.2023.11.883","volume":"153","author":"G Mosnaim","year":"2024","unstructured":"Mosnaim G, Gimenez-Arnau A, Hide M, et al. Efficacy of remibrutinib in patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies. J Allergy Clin Immunol. 2024;153(2):AB369. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.883.","journal-title":"J Allergy Clin Immunol"},{"issue":"5, Supplement","key":"2170_CR52","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.anai.2022.08.594","volume":"129","author":"K Hayama","year":"2022","unstructured":"Hayama K, Ramsey A, Maurer M, et al. Remibrutinib improves chronic spontaneous urticaria in patients with low or high IGE. Ann Allergy Asthma Immunol. 2022;129(5, Supplement):S31\u20132. https:\/\/doi.org\/10.1016\/j.anai.2022.08.594.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"2170_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12227","volume":"13","author":"R Gimeno","year":"2023","unstructured":"Gimeno R, Ribas-Llaurad\u00f3 C, Pesque D, et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of Fc\u03b5R1 expression level and omalizumab clinical response. Clin Transl Allergy. 2023;13(3): e12227. https:\/\/doi.org\/10.1002\/clt2.12227.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"2170_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.anai.2024.03.002","volume":"133","author":"EV Lin","year":"2024","unstructured":"Lin EV, Suresh RV, Dispenza MC. Bruton\u2019s tyrosine kinase inhibition for the treatment of allergic disorders. Ann Allergy Asthma Immunol. 2024. https:\/\/doi.org\/10.1016\/j.anai.2024.03.002.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2170_CR55","doi-asserted-by":"publisher","first-page":"AB373","DOI":"10.1016\/j.jaci.2023.11.893","volume":"153","author":"M Maurer","year":"2024","unstructured":"Maurer M, Gimenez-Arnau A, Ferrucci S, et al. Efficacy and safety of rilzabrutinib in patients with chronic spontaneous urticaria: 12-week results from the RILECSU Phase 2 dose-ranging study. J Allergy Clin Immunol. 2024;153(2):AB373. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.893.","journal-title":"J Allergy Clin Immunol"},{"key":"2170_CR56","unstructured":"Maurer M, Sun I, Schroeder-Lang S, et al. Rilzabrutinib Reduces IgG anti-thyroid peroxidase (anti-TPO), soluble Mas-related G protein-coupled receptor X2 (sMRGPRX2) and eosinophils at 12 weeks in patients with chronic spontaneous urticaria. EAACI Congress 2024 Abstract. 2024. https:\/\/eaaci2024processy-congresscom\/ScientificProcess\/Data\/67\/492\/Abstracts\/292ed479e0efd12128b95eaf46ed3f5ahtml."},{"issue":"6","key":"2170_CR57","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.anai.2024.08.049","volume":"133","author":"M Hide","year":"2024","unstructured":"Hide M, Fukunaga A, Yagami A. Bruton\u2019s tyrosine kinase inhibitor tas5315 showed long-lasting hive-free condition in patients with chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2024;133(6):S7. https:\/\/doi.org\/10.1016\/j.anai.2024.08.049.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2170_CR58","unstructured":"Hide M, Fukunaga A, Yagami A. A randomized, double-blind, phase 2a study of covalent Bruton\u2019s tyrosine kinase inhibitor TAS5315 in patients with chronic spontaneous urticaria with an inadequate response to H1-antihistamines. Presented at EAACI 2024."},{"issue":"23","key":"2170_CR59","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.7150\/thno.46719","volume":"10","author":"P Valent","year":"2020","unstructured":"Valent P, Akin C, Hartmann K, et al. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich\u2019s visions to precision medicine concepts. Theranostics. 2020;10(23):10743\u201368. https:\/\/doi.org\/10.7150\/thno.46719.","journal-title":"Theranostics"},{"issue":"4","key":"2170_CR60","first-page":"965","volume":"142","author":"SJ Galli","year":"1993","unstructured":"Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol. 1993;142(4):965\u201374.","journal-title":"Am J Pathol"},{"issue":"9","key":"2170_CR61","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","volume":"80","author":"P Valent","year":"1992","unstructured":"Valent P, Spanbl\u00f6chl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture. Blood. 1992;80(9):2237\u201345 ((In eng)).","journal-title":"Blood"},{"issue":"2","key":"2170_CR62","doi-asserted-by":"publisher","first-page":"AB366","DOI":"10.1016\/j.jaci.2023.11.873","volume":"153","author":"M Maurer","year":"2024","unstructured":"Maurer M, Kobielusz-Gembala I, Mitha E, et al. Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a phase 2 trial. J Allergy Clin Immunol. 2024;153(2):AB366. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.873.","journal-title":"J Allergy Clin Immunol"},{"key":"2170_CR63","unstructured":"Maurer M, Metz M, Kobielusz-Gembala I, et al. Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria. In: Presented at EADV 2024. https:\/\/celldex.com\/wp-content\/uploads\/CLDX_EADV2024_Congress_Presentation.pdf."},{"key":"2170_CR64","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","volume":"78","author":"D Terhorst-Molawi","year":"2022","unstructured":"Terhorst-Molawi D, Hawro T, Grekowitz E, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2022;78:1269\u201379. https:\/\/doi.org\/10.1111\/all.15585.","journal-title":"Allergy"},{"issue":"15","key":"2170_CR65","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1523\/jneurosci.20-15-05679.2000","volume":"20","author":"SK McLaughlin","year":"2000","unstructured":"McLaughlin SK. Erb and c-Kit receptors have distinctive patterns of expression in adult and developing taste papillae and taste buds. J Neurosci. 2000;20(15):5679\u201388. https:\/\/doi.org\/10.1523\/jneurosci.20-15-05679.2000.","journal-title":"J Neurosci"},{"key":"2170_CR66","unstructured":"Jasper Therapeutics. https:\/\/ir.jaspertherapeutics.com\/static-files\/5b201cb8-2ea5-489c-9634-cbb90e91c6ba. 2023."},{"key":"2170_CR67","doi-asserted-by":"publisher","unstructured":"Darougar S, Hashemitari SK, Montazeri Namin S. Janus-kinase inhibitors in pathogenesis and management of chronic urticaria: a review of the literature. J Pediatr Rev. 2023;11(2):153\u2013162. https:\/\/doi.org\/10.32598\/jpr.11.2.1058.1.","DOI":"10.32598\/jpr.11.2.1058.1"},{"issue":"2","key":"2170_CR68","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","volume":"86","author":"S Chapman","year":"2022","unstructured":"Chapman S, Kwa M, Gold LS, et al. Janus kinase inhibitors in dermatology: part I. A comprehensive review. J Am Acad Dermatol. 2022;86(2):406\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.002.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2170_CR69","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2340\/00015555-3006","volume":"98","author":"A Fukunaga","year":"2018","unstructured":"Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol. 2018;98(9):904\u20135. https:\/\/doi.org\/10.2340\/00015555-3006.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"2170_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15932","volume":"35","author":"P Mansouri","year":"2022","unstructured":"Mansouri P, Mozafari N, Chalangari R, et al. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther. 2022;35(12): e15932. https:\/\/doi.org\/10.1111\/dth.15932.","journal-title":"Dermatol Ther"},{"key":"2170_CR71","first-page":"235","volume":"9","author":"E Shibu","year":"2023","unstructured":"Shibu E, Singh G, Gautam M, Patil S, Godse K. Oral tofacitinib in refractory chronic spontaneous urticaria. IP Indian J Clin Exp Dermatol. 2023;9:235\u20139.","journal-title":"IP Indian J Clin Exp Dermatol"},{"issue":"11","key":"2170_CR72","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3390\/cells10112906","volume":"10","author":"H Ogasawara","year":"2021","unstructured":"Ogasawara H, Noguchi M. Therapeutic potential of MRGPRX2 inhibitors on mast cells. Cells. 2021;10(11):2906. https:\/\/doi.org\/10.3390\/cells10112906.","journal-title":"Cells"},{"issue":"4","key":"2170_CR73","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2022.12.805","volume":"151","author":"M Kumar","year":"2023","unstructured":"Kumar M, Duraisamy K, Annapureddy RR, et al. Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction. J Allergy Clin Immunol. 2023;151(4):1110\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.805.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2170_CR74","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","volume":"138","author":"H Subramanian","year":"2016","unstructured":"Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol. 2016;138(3):700\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2016.04.051.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2170_CR75","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","volume":"134","author":"D Fujisawa","year":"2014","unstructured":"Fujisawa D, Kashiwakura J, Kita H, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol. 2014;134(3):622-633.e9. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2170_CR76","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jid.2020.06.030","volume":"141","author":"M Shtessel","year":"2021","unstructured":"Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria. J Invest Dermatol. 2021;141(3):678\u20136812. https:\/\/doi.org\/10.1016\/j.jid.2020.06.030.","journal-title":"J Invest Dermatol"},{"issue":"8785","key":"2170_CR77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0140-6736(92)91000-x","volume":"339","author":"CH Smith","year":"1992","unstructured":"Smith CH, Atkinson B, Morris RW, et al. Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria. Lancet. 1992;339(8785):91\u20133. https:\/\/doi.org\/10.1016\/0140-6736(92)91000-x.","journal-title":"Lancet"},{"issue":"6","key":"2170_CR78","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/all.15270","volume":"77","author":"M Babina","year":"2022","unstructured":"Babina M, Wang Z, Li Z, et al. Fc\u03b5RI- and MRGPRX2-evoked acute degranulation responses are fully additive in human skin mast cells. Allergy. 2022;77(6):1906\u20139. https:\/\/doi.org\/10.1111\/all.15270.","journal-title":"Allergy"},{"issue":"8","key":"2170_CR79","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","volume":"11","author":"K-W Chuang","year":"2023","unstructured":"Chuang K-W, Hsu C-Y, Huang S-W, et al. Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023;11(8):2382\u201323893. https:\/\/doi.org\/10.1016\/j.jaip.2023.05.033.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10450","key":"2170_CR80","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gim\u00e9nez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024;404(10450):393\u2013404. https:\/\/doi.org\/10.1016\/S0140-6736(24)00852-3.","journal-title":"Lancet"},{"issue":"3","key":"2170_CR81","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.jacig.2024.100249","volume":"3","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Urakami T, Ishimaru K, et al. A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation. J Allergy Clin Immunol Glob. 2024. https:\/\/doi.org\/10.1016\/j.jacig.2024.100249.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"4","key":"2170_CR82","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","volume":"142","author":"M Godar","year":"2018","unstructured":"Godar M, Deswarte K, Vergote K, et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol. 2018;142(4):1185. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2170_CR83","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41467-023-44373-x","volume":"15","author":"L Zhu","year":"2024","unstructured":"Zhu L, Jian X, Zhou B, et al. Gut microbiota facilitate chronic spontaneous urticaria. Nat Commun. 2024;15(1):112. https:\/\/doi.org\/10.1038\/s41467-023-44373-x.","journal-title":"Nat Commun"},{"issue":"1","key":"2170_CR84","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/s41467-021-22834-5","volume":"12","author":"E Conde","year":"2021","unstructured":"Conde E, Bertrand R, Balbino B, et al. Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice. Nat Commun. 2021;12(1):2574. https:\/\/doi.org\/10.1038\/s41467-021-22834-5.","journal-title":"Nat Commun"},{"issue":"5, Supplement","key":"2170_CR85","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.anai.2022.08.578","volume":"129","author":"A Abadeh","year":"2022","unstructured":"Abadeh A, Lee J. Dupilumab as a potential disease-modifying intervention for chronic spontaneous urticaria: 3-year follow-up results. Ann Allergy Asthma Immunol. 2022;129(5, Supplement):S26. https:\/\/doi.org\/10.1016\/j.anai.2022.08.578.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"2170_CR86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67\u201375. https:\/\/doi.org\/10.1038\/jid.2014.306.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"2170_CR87","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1215372.","journal-title":"N Engl J Med"},{"issue":"1","key":"2170_CR88","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2013.05.013.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02170-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:54:46Z","timestamp":1743288886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02170-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02170-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"23 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.K. was a speaker\/consultant and\/or advisor for and\/or has received research funding from BioCryst, Merus, Novartis, ValenzaBio, and Roche outside of the submitted work. J.F. was a speaker, advisor for, and\/ or has received honoraria and\/or travel sponsorship from CSL Behring, Takeda, Novartis, Menarini, and Viatris outside of the submitted work. E.K. is\/was a speaker and advisor for Novartis, Menarini, LaRoche Posey, Sanofi, Bayer, Abdi \u0130brahim, and Pfizer outside of the submitted work. P.H.L. was a speaker, advisor for, and has received research funding from Novartis and Sanofi outside of the submitted work. T.L.O. has recieved travel sponsorship from Novartis, Takeda, and Menarini outside of the submitted work. J.M. was a speaker, advisor for, and\/ or has received travel sponsorship from Novartis, Sanofi, Takeda, Menarini, AstraZeneca, GlaxoSmithKline, Roxall, Bial, and Medinfar. M.M. is or recently was a speaker and\/or advisor for: AbbVie, Advanz, ALK-Abello, Allegria, Almirall, Amgen, Argenx, AstraZeneca, Astria, Attovia, Berlin-Chemie, Celldex, Celltrion, DeepApple, Escient, Galderma, GSK, Incyte, Jasper, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Santa Ana Bio, Septerna, Teva, ThirdHarmonicBio, and Vifor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material:"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"P.K. and M.M. conceived the idea for the review. These authors researched data for the article and worked on the specific parts of the manuscript: P.K. (introduction, conclusion, tables), J.S.F. (anti-KIT), E.K. (BTK inhibitors), P.H.L. (other drugs), T.-L.O. (anti-IL4R\u03b1), and J.M. (other drugs). P.K. combined all parts of the manuscript and wrote the first version of the manuscript under the supervision of and input from M.M. All authors provided feedback on the first draft of the manuscript and its revision and contributed to the discussion of the content. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}